Merck-Backed Lab Gets $8.5 Million to Fast-Track a Vaccine For a Rapidly Spreading Ebola Outbreak
Merck and Wellcome-backed Hilleman will manufacture Bundibugyo Ebola vaccine doses for clinical trials with up to $8.5M in CEPI funding.
A company backed by Merck got money to quickly make and test a new Ebola vaccine for an outbreak. This shows Merck is investing in fighting serious diseases, which can help its reputation and business long-term.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.